Advertisement
Organisation › Details
Inthera Bioscience AG
Inthera Bioscience is a private biopharmaceutical company focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. Rationally designed, these orally bioavailable molecules display hot spot residues on a non-peptidic backbone merging the versatility of small molecules with the specificity of biologics. The broad applicability of the approach has been illustrated against several targets in oncology. Inthera’s lead programs focus on HPV-associated cancers and hypoxia-inducible signaling. *
Start | 2013-09-20 established | |
Industry | small-molecule cancer drug | |
Industry 2 | drug development | |
Person | Kessler, Ulrich (Inthera Bioscience AG 201512 CEO + Co-founder) | |
Person 2 | Schollmeier, Klaus (SuppreMol 201304– Managing Director before Santhera CEO + ING BHF-Bank + Abbott/Knoll/BASF) | |
Region | Zürich ZH | |
Country | Switzerland | |
Street | 11 Gartenstr. | |
City | 8002 Zürich ZH | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Inthera Bioscience AG. (5/31/17). "Press Release: Inthera Bioscience Raises CHF 10.5 Million in Series A Financing Round". Zurich. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Inthera Bioscience AG
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top